Search
RUS 3108
go.drugbank.com/drugs/DB05911ExperimentalRUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
5-methyltetrahydrofolic acid
go.drugbank.com/drugs/DB04789InvestigationalNutraceuticalIt is generated by methylenetetrahydrofolate reductase from 5,10-methylenetetrahydrofolate and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferases
Difluprednate
go.drugbank.com/drugs/DB06781ApprovedInvestigationalDifluprednate is a topical corticosteroid indicated for the treatment of infammation and pain associated with ocular surgery. It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or diflu...
Torcetrapib
go.drugbank.com/drugs/DB06281InvestigationalTorcetrapib (CP-529414, Pfizer) was developed to treat hypercholesterolemia but its development was halted in 2006 when phase III studies showed excessive mortality in the treatment group receiving a combination
PlasmaCord
go.drugbank.com/drugs/DB16363ExperimentalPlasmaCord is platelet-poor plasma that is derived by fractionation from sterile umbilical cord and placental blood. … [L27581] It is developed by Cellpraxis and is currently being investigated against severe acute respiratory syndrome (SARS).
Picolinic acid
go.drugbank.com/drugs/DB05483ExperimentalIt acts as an anti-infective and immunomodulator and is produced in approximately 25-50 mg quantities by the body on a daily basis through the breakdown of tryptophan. … As a therapeutic agent, the molecule works by binding to zinc finger proteins (ZFPs) in a way that changes their structures and disrupts zinc binding, inhibiting function.
Ponazuril
go.drugbank.com/drugs/DB11452ExperimentalVet approvedPonazuril, sold by the Bayer Corporation under the trade name Marquis, is a drug currently approved for the treatment of equine protozoal myeloencephalitis in horses, caused by Sarcocystis neurona.
Pomaglumetad methionil
go.drugbank.com/drugs/DB05096InvestigationalMost currently approved antipsychotic medications work by affecting the neurotransmitters dopamine or serotonin. … For LY2140023, the active substance, LY404039, is thought to work by reducing the presynaptic release of another neurotransmitter, glutamate, in brain regions where mGlu2/3 receptors are expressed.
Ibuzatrelvir
go.drugbank.com/drugs/DB19451InvestigationalIbuzatrelvir is under investigation in clinical trial NCT06679140 (A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized but
Inebilizumab
go.drugbank.com/drugs/DB12530ApprovedInvestigationalInappropriate growth of or self-directed antibody production by B-cells is the etiological underpinning of a variety of conditions, including the multiple sclerosis-like neurological condition neuromyelitis … [L49861] In April 2025, inebilizumab was additionally approved by the FDA for immunoglobulin G4-related disease (IgG4-RD).[L52705,L14315] It is the first and only FDA-approved treatment for IgG4-RD.